Bacterial vaginosis. Modern view of the problem and its status in Ukraine

Authors

DOI:

https://doi.org/10.18370/2309-4117.2021.59.72-77

Keywords:

bacterial vaginosis, patient survey, abnormal discharge, Gardnerella vaginalis, diagnosis, treatment

Abstract

Research objective: to examine the incidence of asymptomatic and recurrent bacterial vaginosis (BV) in Ukrainian women and to evaluate diagnostic and treatment strategies for the disease control.
Materials and methods. This study lasted from January to March 2021 and included 277 doctors of women's clinics, gynecological hospitals and oncology centers from all regions of Ukraine. Information was provided on 12 896 patients between of 18 and 59 ages with BV.
Results. Analysis of data from 12 896 questionnaires allowed us to determine that women from 18 to 35 years of age (62.6%) were the most frequently consulted about BV. Only 58.72% patients with BV reported about abnormal vaginal discharge as the reason for visit, while 41.24% of the respondents reported other reasons. Questionnaire analysis of patients with vaginal discharge revealed scant symptoms of the disease: only 62.67% complained about the change of discharge character; 38.49% and 36.35% of examinees pointed to the vaginal itching and unpleasant odor, respectively; 19.89% of patients were troubled by dysuric symptoms and 15.10% of patients mentioned dyspareunia.
In the list of submitted questionnaires, 59.92% of patients indicated an additional examination to identify the causes of vaginitis by the PCR method (urogenital scraping). According to its results, Gardnerella vaginalis was detected in diagnostically significant concentrations in 71.49% of patients, Atopobium vaginae was found in 11.32% of cases, Mobiluncus spp. was detected in 19.96% of patients and
Trichomonas vaginalis was found in 13.12% of patients. Candida colonization was diagnosed in 62.07%, with Candida albicans in 48,52% cases and non-albicans forms in 13,55% of patients.
In the treatment of BV priority was given to the vaginal forms of the most compliant therapy regimens: 2 times a day for 3 days or once a day for 7 days, depending on the clinical situation. Some patients opted for a long course of treatment for recurrent infections, choosing the combination metronidazole 750 mg / miconazole 200 mg 1 suppository once a day for 5 days for 12 months.
Conclusion. Diagnosis of BV in Ukraine continues to be based on clinical conditions and requires a unified algorithm that will be based on current clinical guidelines and dictated by national protocols for management. High mycotic colonization (62,07%) in BV makes it expedient to use combined agents (metronidazole 750 mg / miconazole 200 mg tioconazole/tinidazole) both as etiotropic and empirical therapy and especially if there are clinical conditions that may can cause BV (before surgical interventions, after antibiotic therapy, in endocrine pathology, etc.).

Author Biographies

L.V. Kalugina, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”, Kyiv

MD, leading researcher, Endocrine Gynecology Department

T.F. Tatarchuk, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”; SSI “CIMT of the NAS of Ukraine”, Kyiv

MD, professor, corresponding member of the NAMS of Ukraine, deputy director for research work, head of the Endocrine Gynecology Department;

Chief researcher, Department of Reproductive Health

I.V. Shmulian, Clinic “Verum”, Kyiv

Obstetrician-gynecologist

References

  1. Hardy, L., et al. “A fruitful alliance: the synergy between Atopobium vaginae and Gardnerella vaginalis in bacterial vaginosis-associated biofilm.” Sex Transm Infect 92 (2016): 487–91. DOI:10.1136/sextrans-2015-052475
  2. Tatarchuk, T.F., Kalugina, L.V., Petrova, G.A., et al. “Vaginal discharge syndrome. The problem with many unknowns.” Reproductive Endocrinolog 3.53 (2020): 102–8. DOI: 10.18370/2309-4117.2020.53.102-108
  3. Dingens, A.S., Fairfortune, T.S., Reed,,S., et al. “Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study.” BMC Pregnancy Childbirth 16 (2016): 278.
  4. Haddad, L.B., Wall, K.M., Kilembe, W., et al. “Bacterial vaginosis modifies the association between hormonal contraception and HIV acquisition.” AIDS 32 (2018): 595–604.
  5. Coudray, M.S., Madhivanan, P. “Bacterial Vaginosis. A Brief Synopsis of the Literature.” European Journal of Obstetrics & Gynecology and Reproductive Biology 245 (2020): 143–8. DOI: 10.1016/j.ejogrb.2019.12.035
  6. Liang, Y., Chen, M., Qin, L., et al. ”A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia.” Infect Agents Cancer 14.29 (2019). DOI: 10.1186/s13027-019-0243-8
  7. Bradshaw, C., Sobel, J. “Current treatment of bacterial vaginosis. Limitations and need for innovation.” J Infect Dis 214 (2016): S14–S20.
  8. Ulitin, I.B., Bovykina, G.A., Ulitina, E.P. “Bacterial vaginosis as a cofactor of intraepithelial neoplasia.” In: Materials of III National Congress “Oncology of the reproductive organs: from prevention and early detection” (2018).
  9. Ranjit, E., Raghubanshi, B.R., Maskey, S., Parajuli, P. “Prevalence of Bacterial Vaginosis and Its Association with Risk Factors among Nonpregnant Women: A Hospital Based Study.“ Int J Microbiol 2018 (2018): 8349601.
  10. Zozaya, M., Ferris, M.J., Siren, J.D., et al. “Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis.” Microbiome 4 (2016): 16.
  11. Machado, A., Cerca, N. “Influence of biofilm formation by Gardnerella vaginalis and other anaerobes on bacterial vaginosis.” J Infect Dis 212 (2015): 1856–61.
  12. van Schalkwyk, J., Yudin, M.H. “Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis.” J Obstet Gynaecol Can 37.3 (2015): 266–74.
  13. Dikke, G.B. “Bacterial vaginosis: new aspects of etiopathogenesis and choice of therapeutic strategies for breast cancer.” Mother and child 2.4 (2019). DOI: 10.32364/2618-8430-2019-2-4-307-313
  14. Vaneechoutte, M., Guschin, A., Van Simaey, L., et al. “Emended description of Gardnerella vaginalis and description of Gardnerella leopoldii sp. nov., Gardnerella piotii sp. nov. and Gardnerella swidsinskii sp. nov., with delineation of 13 genomic species within the genus Gardnerella.” Int J Syst Evol Microbiol 69 (2019): 679–87.
  15. Khan, S., Voordouw, M.J., Hill, J.E. “Competition among Gardnerella subgroups from the human vaginal microbiome”. Front Cell Infect Microbiol (2019). DOI: 10.3389/fcimb.2019.00374
  16. Hill, J., Albert, A.Y.K.; VOGUE Research Group. “Resolution and co-occurrence patterns of Gardnerella leopoldii, Gardnerella swidsinskii, Gardnerella piotii and Gardnerella vaginalis within the vaginal microbiome.” Infect Immun (2019). DOI: 10.1128/IAI.00532-19
  17. Muzny, C.A., Blanchard, E., Taylor, C.M., et al. “Identification of key bacteria involved in the induction of incident bacterial vaginosis: a prospective study.” J Infect Dis 218 (2018): 966–78.
  18. Muzny, C.A., Lensing, S.Y., Aaron, K.J., et al. “Incubation period and risk factors support sexual transmission of bacterial vaginosis in women who have sex with women.” Sex Transm Infect 95 (2019): 511–5.
  19. Edwards, V.L., Smith, S.B., McComb, E.J., et al. “The cervicovaginal microbiota-host interaction modulates Chlamydia trachomatis infection.” MBio 10 (2019): e01548-19.
  20. Muzny, C.A., Taylor, C.M., Swords, W.E., et al. “An updated conceptual model on the pathogenesis of bacterial vaginosis.” J Infect Dis 220 (2019): 1399–05.
  21. Sherrard, J., Wilson, J., Donders, G., et al. “European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge.” International Journal of STD & AIDS 29.13 (2018): 1258–72.
  22. Martin, D.H., Marrazzo, J.M. “The Vaginal Microbiome: Current Understanding and Future Directions.” The Journal of infectious diseases 214 Suppl 1 (2016): S36–41.
  23. Coleman, J.S., Gaydos, C.A. “Molecular diagnosis of bacterial vaginosis: an update.” Microbiol 56 (2018): e00342–18.
  24. Australian STI Management guidelines for use in primary care. Bacterial vaginosis. Available from: [http://www.sti.guidelines.org. au/sexually-transmissible-infections/infections-associated-with-sex/bacterial-vaginosis].
  25. Onderdonk, A.B., Delaney ,M.L., Fichorova, R.N. “The human microbiome during bacterial vaginosis.” Clin Microbiol Rev 29 (2016): 223–38. DOI: 10.1128/CMR.00075-15
  26. Sobel, J.D., Sobel, R. “Current and emerging pharmacotherapy for recurrent bacterial vaginosis.” Expert Opinion on Pharmacotherapy (2021). DOI: 10.1080/14656566.2021.1904890
  27. Denning, D.W., Kneale, M,. Sobel, J.D., et al. “Global burden of recurrent vulvovaginal candidiasis: a systematic review.” Lancet Infect Dis 18 (2018): e339–47.
  28. Hauser, A.R., Mecsas, J., Moir, D.T. “Beyond antibiotics: new therapeutic approaches for bacterial infections.” Clin Infect Dis 63 (2016): 89–95.
  29. Casadevall, A., Kontoyiannis, D.P., Robert, V. “On the emergence of Candida auris: climate change, azoles, swamps, and birds.” MBio 10 (2019): 7e01397–19.
  30. Johnston, C., Gottlieb, S.L., Wald, A. “Status of vaccine research and development of vaccines for herpes simplex virus.” Vaccine 34 (2016): 2948–52.
  31. González-Bello, C. “Antibiotic adjuvants – a strategy to unlock bacterial resistance to antibiotics.” Bioorg Med Chem Lett 27 (2017): 4221–8.
  32. Thellin, O., Zorzi, W., Zorzi, D., et al. “Lysozyme as a cotreatment during antibiotics use against vaginal infections: an in vitro study on Gardnerella vaginalis biofilm models.” Int Microbiol 19 (2016): 101–7.
  33. Vrynchanu, N.O., Grinchuk, N.I., Samsonova, V.V. “The effect of Distreptase Distrept on the antibiotic activity of clindamycin against Staphylococcus Spp." Reproductive endocrinology 56 (2020): 43–6. DOI: 10.18370/2309-4117.2020.56.43-46
  34. Weeks, R.M., Moretti, A., Song, S., et al. “Cationic amphiphiles against Gardnerella vaginalis resistant strains and bacterial vaginosis-associated pathogens”. Pathog Dis (2019): ftz059.
  35. Tomás, M., et al. “Bacterial vaginosis: Standard treatments and alternative strategies.” International Journal of Pharmaceutics (2020). DOI: 10.1016/j.ijpharm.2020.119659

Downloads

Published

2021-07-22

How to Cite

Kalugina, L., Tatarchuk, T., & Shmulian, I. (2021). Bacterial vaginosis. Modern view of the problem and its status in Ukraine. REPRODUCTIVE ENDOCRINOLOGY, (59), 72–77. https://doi.org/10.18370/2309-4117.2021.59.72-77

Issue

No. 59 (2021)

Section

Gynecology

License

Copyright (c) 2021 Л.В. Калугіна, Т.Ф. Татарчук, І.В. Шмулян

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.